Center on Health Equity & Access

Orbital rhabdomyosarcoma survival held steady despite less-intensive chemo and radiation, according to 25-year data.

AI-driven platform boosts screening capacity 41%, cuts manual review by 75% across Ochsner's 47 hospitals and 370 clinics.

A study shows mobile integrated health was well received by patients and clinicians despite barriers to broader implementation.

How states can partner with free clinics and other local programs to realign incentives for uninsured patients.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.

Clinicians at a Chicago Population Health Roundtable say atopic dermatitis biologic therapy is delayed by several key obstacles.

County-level CRC mortality was higher in areas with limited broadband access, higher smoking rates, and rurality.

Frequent adolescent sexual assault and discrimination in employment, housing, and police interactions was associated with higher heart failure risk.

Low fruit and vegetable intake alongside high sodium consumption remain top dietary drivers of CKD burden, with disparities by region, age, and income.

William Schaffner, MD, explains why declining childhood vaccination rates are fueling the resurgence of measles and other preventable diseases.

Hepatitis B re-engagement efforts are underreported in lower-resource settings, highlighting gaps in care and the need for greater action.

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change for children with the disease.

Roundtable reveals vitiligo care gaps: Opzelura leads, insurers still call it cosmetic, and pricey oral JAKs near approval—what’s next?

Most eligible people with multiple sclerosis have never used GLP-1 receptor agonists, despite their potential cardiometabolic benefits.

Closed-loop referral systems confirm outcomes, not just referrals, avoiding false success and building durable, scalable social care infrastructure.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

She frames the IberDd approval as more than the addition of 1 more regimen to a crowded relapsed/refractory myeloma armamentarium.

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

Full-risk Medicare Advantage models outperform traditional Medicare for socially vulnerable beneficiaries, explains Ken Cohen, MD, of Optum Health.

Although new guidelines call for universal screening, most Americans with elevated Lp(a) still don't know their number.